Future to develop more assays for Bayer:
This article was originally published in Clinica
Future Diagnostics has won a contract from Bayer Healthcare's diagnostics division to develop a suite of immunoassays for use on the German multinational's line of Advia Centaur analyser systems. In the first phase of the agreement, Future Diagnostics, of Wijchen, the Netherlands, will develop four immunoassays: two fertility tests - one for sex hormone-binding globulin (SHBG) and another for dehydroepiandrosterone sulfate (DHEA); an unconjugated estriol (uE3) test to monitor foetal maturity and well-being; and an assay that detects the D-dimer marker linked to deep vein thrombosis or pulmonary embolism. Future Diagnostics had a previous agreement with Bayer in 2001, when it developed an intact parathyroid (PTH) assay for diagnosis of metabolic bone disease.
You may also be interested in...
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
New round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.